Streetbeat News

Stock Prices

ALT

EYPT

OCUL

OMER

TERN

Five health care stocks with high RSI values, indicating potential overbought conditions, have seen significant price movements. EyePoint Pharmaceuticals (EYPT) surged after Phase 2 trial results, Altimmune (ALT) gained on obesity trial results, Omeros Corporation (OMER) rose despite a wider Q3 loss, Terns Pharmaceuticals (TERN) increased after a narrower quarterly loss, and Ocular Therapeutix (OCUL) advanced on a narrower-than-expected quarterly loss.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 2:05 pm

DIS

Ancora Holdings Group LLC, a shareholder of The Walt Disney Company (DIS), has issued a letter to fellow shareholders advocating for the addition of an investor representative to Disney's Board. Ancora criticizes Disney's recent performance and governance, highlighting the company's underperformance compared to the S&P 500 Media & Entertainment Index and its polarizing brand actions. They suggest that Trian Fund Management and Nelson Peltz could provide valuable oversight during Disney's transformation. Ancora also discredits Blackwells Capital LLC's recent attack on Peltz, contrasting it with Peltz's successful history in shareholder activism.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 2:04 pm

GTLB

GitLab Inc. (GTLB) shares surged over 16% in pre-market trading following the release of Q3 earnings that surpassed expectations and a strong FY24 forecast. The company reported earnings of $0.09 per share against expected losses of $0.01 per share, with sales of $149.70 million beating estimates of $141.49 million. GitLab anticipates FY24 earnings of $0.12 to $0.13 per share, compared to expected losses of $0.06 per share, and revenue projections of $573 million to $574 million, above the $558.14 million estimate.

Portfolio Pulse from Lisa Levin

December 05, 2023 | 2:04 pm

GTLB

GitLab Inc (NYSE:GTLB) stock is trading higher after reporting Q3 financial results that exceeded expectations and providing an optimistic outlook. Q3 revenue was $149.7 million, surpassing estimates of $141.49 million, with EPS at 9 cents beating the expected loss of 1 cent. Year-over-year revenue increased by 32%, with significant growth in customers across different ARR thresholds. CEO Sid Sijbrandij highlighted the adoption of GitLab's DevSecOps Platform. The company forecasts Q4 revenue between $157 million and $158 million and EPS of 8 to 9 cents, both above estimates. Full-year revenue is expected to be between $573 million and $574 million with EPS of 12 to 13 cents, again surpassing estimates. Barclays analyst Ryan Macwilliams maintained an Equal-Weight rating on GitLab but raised the price target from $50 to $55.

Portfolio Pulse from Adam Eckert

December 05, 2023 | 2:01 pm

OLLI

Ollie's Bargain Outlet (NASDAQ:OLLI) is expected to release its quarterly earnings report on Wednesday, 2023-12-06, with an estimated EPS of $0.44. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, OLLI's stock price has shown mixed reactions to earnings reports. Shares are currently trading at $76.28, up 60.24% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 2:01 pm

GME

GameStop (NYSE:GME) is scheduled to release its quarterly earnings report on Wednesday, 2023-12-06, with an estimated EPS of $-0.08. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, GameStop's share price has been sensitive to earnings performance and guidance. Last quarter, GME beat the EPS estimate, resulting in a 0.75% share price increase the following day. Over the last year, GME shares have declined by 23.94%.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 2:01 pm

CHPT

ChargePoint Holdings (NYSE:CHPT) is scheduled to release its quarterly earnings report on December 6, 2023. Analysts predict an EPS of $-0.22. Investors are looking for an earnings beat and positive guidance for the next quarter. ChargePoint's stock price historically reacts to earnings performance and guidance. Last quarter, the company missed EPS estimates by $0.09, resulting in a 10.91% share price drop the following day. Over the past year, CHPT shares have declined by 80.75%, trading at $2.09 as of December 4.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 2:01 pm

AGX

Argan (NYSE:AGX) is scheduled to release its quarterly earnings report on Wednesday, 2023-12-06. Analysts predict an EPS of $0.88. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, Argan's stock price has been sensitive to earnings performance and guidance. Last quarter, Argan beat the EPS estimate by $0.20, leading to a 9.18% stock price increase the following day. Over the past year, AGX shares have risen 26.58%, with the stock trading at $47.15 as of December 01.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 2:01 pm

BRZE

Braze (NASDAQ:BRZE) is expected to release its quarterly earnings report on Wednesday, 2023-12-06, with an estimated EPS of $-0.13. Investors are looking for an earnings beat and positive guidance for future growth. Historically, Braze has surpassed EPS estimates, leading to share price increases, except for Q3 2023. Shares are currently trading at $56.68, with a 125.82% increase over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 2:01 pm

NURO

NeuroMetrix has announced that its Phase 2 clinical trial results, which show that Quell, its wearable pain relief device, improves symptoms of chemotherapy-induced peripheral neuropathy (CIPN), have been published in a peer-reviewed journal. This publication could potentially boost the credibility of Quell and NeuroMetrix's standing in the medical community.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 2:01 pm